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Abstract
Background: Studies have observed an association between the ABO blood group and risk of certain malignancies.
However, no studies of the association with hepatocellular carcinoma (HCC) risk are available. We conducted this hospital-
based case-control study to examine the association with HCC in patients with chronic hepatitis B (CHB).
Methods: From January 2004 to December 2008, a total of 6275 consecutive eligible patients with chronic hepatitis B virus
(HBV) infection were recruited. 1105 of them were patients with HBV-related HCC and 5,170 patients were CHB without
HCC. Multivariate logistic regression models were used to investigate the association between the ABO blood group and
HCC risk.
Results: Compared with subjects with blood type O, the adjusted odds ratio (AOR) for the association of those with blood
type A and HCC risk was 1.39 [95% confidence interval (CI), 1.05–1.83] after adjusting for age, sex, type 2 diabetes, cirrhosis,
hepatitis B e antigen, and HBV DNA. The associations were only statistically significant [AOR (95%CI)=1.56(1.14–2.13)] for
men, for being hepatitis B e antigen positive [AOR (95%CI)=4.92(2.83–8.57)], for those with cirrhosis [AOR (95%CI),
1.57(1.12–2.20)], and for those with HBV DNA#10
5copies/mL [AOR (95%CI), 1.58(1.04–2.42)]. Stratified analysis by sex
indicated that compared with those with blood type O, those with blood type B also had a significantly high risk of HCC
among men, whereas, those with blood type AB or B had a low risk of HCC among women.
Conclusions: The ABO blood type was associated with the risk of HCC in Chinese patients with CHB. The association was
gender-related.
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Introduction
Hepatocellular carcinoma (HCC) is one of the few cancers with
well-defined major risk factors, including chronic hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection, and cirrhosis due to
many causes [1]. However not all patients with these diseases will
develop HCC. Therefore within these disease groups, there are
other factors that indicate greater or lesser risk[2]. In China, a
hyper-endemic area of HBV infection, nearly 80% of HCC cases
have been linked to chronic HBV infection, and approximately
60%–90% of these develop in patients with cirrhosis [3,4]. Older
age, male sex, cirrhosis and sustained activity of liver disease are
important predicators for HCC[5]. In patients with chronic HBV
infection, HBV DNA level, viral genotype, and hepatitis B e
antigen (HBeAg) status have been identified as risk factors for
HCC [6,7,8]. Other potential risk factors, such as diabetes
mellitus, alcohol abuse, obesity, and family history of liver cancer
may also play a role in the development of HCC [2,9]. As for
human genetic factors, polymorphisms of tumor necrosis factor-a
(TNF-a) and epidermal growth factor (EGF) gene have been
reported to be associated with HCC risk [10,11,12].
The ABO blood group has been previously found to be
associated with the risk of several malignancies, including gastric
cancer, pancreatic cancer, epithelial ovarian and skin cancer[13].
However, there is little data about the association with HCC risk.
Two recent genome-wide association studies (GWAS) suggest that
the ABO blood group antigen may affect the systemic inflamma-
tory state. Single nucleotide polymorphisms (SNPs) at the ABO
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TNF-a and soluble intercellular adhesion molecule 1 (sICAM-1)
[14,15]. Enhanced expression of TNF-a is associated with liver
inflammation and hepatocarcinogenesis[16], also plasma levels of
sICAM-1 are not only associated with the risk of incident diabetes
and liver disease activity, known predisposing factors for HCC, but
furthermore are also a predictive marker of HCC occurrence and
prognosis [17,18,19,20,21,22]. These indicate a possible link
between the ABO blood group and HCC risk, especially in the
presence of other etiological risks for HCC. We hypothesized that
certain serotypes of the ABO blood group might provide
additional risk of HCC development in the presence of CHB.
So, the aim of this case-control study was to examine the
association between the ABO blood group and HCC risk among
patients with CHB.
Materials and Methods
Study population
This case-control study was part of an ongoing hospital-based
prospective investigation [23] that was conducted in Jinan
Infectious Disease Hospital, Shandong University, a tertiary
hospital in Shandong Province, China. The study was approved
by the ethics committee of Jinan Infectious Disease Hospital,
Shandong University, and written informed consent for partici-
pation was obtained from each study participant.
Subjects who fulfilled the following criteria were recruited into
the study: hospitalized for HCC or CHB, age $30 years, positive
for hepatitis B surface antigen (HBsAg), negative for anti-HCV,
without a history or other evidence of cancer other than HCC,
without a history or other evidence of hepatitis other than hepatitis
B, without a history of alcohol consumption, no cancer treatment,
and no treatment with nucleotide/nucleosides or interferon, Han
population and residence of Shandong Province.
From January 2004 and December 2008, a total of 6,275
consecutive eligible patients (1,105 HBV-related HCC and 5170
CHB without HCC) were enrolled. 882 eligible patients were not
recruited because of patient refusal or patient sickness. Statistical
analyses indicated that the eligible patients who were not recruited
did not differ from the recruited patients in term of demographic
and clinical features (retrieved from patients’ medical records).
A total of 1105 HBV-related HCC patients were used as the
case in the study. The 5170 hospital cross-sectional CHB patients
without HCC were used as the control.
Study variables
The variables analyzed in this study included age, sex, city of
residence, family history of liver cancer, type 2 diabetes, hepatitis
B e antigen (HBeAg), cirrhosis, HBV DNA level, and the ABO
blood group. Biochemical parameters related to impaired liver
function, such as, bilirubin, albumin, and prothrombin time, were
also analyzed to explore the relationship between the ABO blood
group and severity of liver disease.
Upon entry to the hospital, all subjects were interviewed by
trained physicians. Demographic data, family histories, and
medical histories were collected. Physical examinations, blood
counts, the ABO blood type, Rh factor, serum biochemical
parameters, prothrombin time, serum alpha-fetoprotein (AFP),
anti-HCV (AxSYM HCV, version 3.0, Abbott Laboratories,
Abbott Park, IL, USA), hepatitis B surface antigen (HBsAg), anti-
HBs, HBeAg, anti-HBe, and anti-HBc (Abbott Laboratories) were
all measured. HBV DNA quantification (Roche COBAS HBV
Amplicor Monitor assay), ultrasound examinations, and gastroin-
testinal barium meal X-ray examinations were also performed.
First-degree relatives (parents, siblings, and children) with liver
cancer were considered to have a positive family history of liver
cancer. Subjects with a fasting blood sugar level of at least
7.0 mmol/L on at least two occasions or those diagnosed with type
2 diabetes before entering the hospital were defined as having type
2 diabetes. At the hospital, a standardized questionnaire was used
to interview the patients about their history of alcohol drinking,
including drinking frequency, average monthly intake of each type
of alcoholic beverage. We assessed total alcohol intake according
to the average ethanol content, by volume, of beer (4–5 percent),
wine (grape wine, rice wine 8–12 percent), and liquor(38–60
percent)[24]. Subjects with an ethanol intake of 30 g/d or more
for men and 20 g/d or more for women for longer than 10 years
were considered to have a positive history of alcohol consumption.
A structured questionnaire was used to record the information
collected.
Diagnosis of HCC and Cirrhosis
The criteria for diagnosis of HCC were positive histology or
cytology, two image findings showing HCC from different
sources [ultrasonography, enhanced computed tomography
(CT) scan, or magnetic resonance imaging(MRI)], or serum
AFP level greater than 400 ng/mL in combination with one
positive image finding. Image diagnosis for HCC was based on
the following classic imaging manifestations: early enhancement
at the arterial phase and hypoattenuation at the portal venous
phase or at the equilibrium phase on contrast-enhanced dynamic
CT or MRI, and hyperattenuation on CT during hepatic
arteriography and hypoattenuation on CT during arterial
portography. Of these 1,105 cases, 298 cases were diagnosed
by histological pathology, 364 cases with an enhanced computed
tomography scan and magnetic resonance imaging, and 443 cases
with a finding of AFP higher than 400 ng/mL in combination
with an abnormal finding from an enhanced computed
tomography scan or ultrasonography.
Diagnosis of cirrhosis was based on liver biopsy or clinical
findings combined with at least one image finding from
ultrasonography or a computed tomography scan. In 386 CHB
patients with a biopsy, the diagnosis of cirrhosis was based on liver
histology according to the criteria of Desmet et al. [25]. In those
patients without biopsy specimens, the diagnosis of cirrhosis was
based on clinical and morphological criteria, ultrasound or
computed tomography, according to standard definitions[26].
These included the presence of clinical manifestations of portal
hypertension (e.g., esophageal varices, encephalopathy, or ascites),
biochemical abnormalities (e.g., decreased serum albumin and
platelets or prolonged prothrombin time), and obvious morpho-
logical changes in the liver detected by hepatic imaging (e.g.,
ultrasonography or computed tomography scan). Minor signs were
also clinically noted, such as palmar erythema, spider angioma,
and clubbing of the fingers. Ultrasonography was performed by
experienced radiologists for every patient upon entry to the
hospital. The severity of cirrhosis was evaluated using Child-Pugh
score[27].
Statistical Analysis
Demographic and clinical parameters were evaluated using the
chi-squared test for categorical variables, independent-Samples t-
test for continuous variables with normal distribution, and the
Mann-Whitney U test or Kruskal-Wallis test for continuous
variables with skewed distribution. Possible confounding effects
among the variables were adjusted using a multivariate logistic
regression model, and adjusted odds ratios (AORs) and 95%
confidence intervals (CI) were calculated. Effect modifications
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by including main effect variables and their product terms in the
logistic regression model. For all tests, P values were 2 sided. A P
value of less than 0.05 was considered significant. All data analyses
were performed using SPSS v. 13.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient Characteristics
The demographic and clinical characteristics of HCC cases and
CHB controls are summarized in Table 1. As expected, most
HCC patients were male (84.7%), HBeAg negative (76.8%), and
cirrhotic (68.7%). The prevalence of HBV DNA.10
5copies/mL
were lower among cases than among controls. Cases and controls
had a similar distribution of family history of liver cancer and city
of residence (Jinan and other cities of Shandong Province). HCC
patients were older than controls, the mean age 6 standard
deviation was 53.869.3 years for patients with HCC and
44.9610.7 years for controls (P,0.001).
ABO blood group and HCC risk
Distributions of blood types O, A, AB, and B are shown in
Table 2. The distribution of blood type A was higher among
HCC cases than among CHB controls (29.0% vs 24.9%,
P=0.013), whereas, the distribution of blood type O, AB, and B
was similar between cases and controls. Compared with subjects
with blood type O, the unadjusted OR for the association of those
with blood type A and HCC risk was 1.31(95% CI, 1.06–1.61). In
multivariable logistic regression, the AOR was 1.39(95%CI, 1.05–
1.83) after adjusting for age, sex, type 2 diabetes, cirrhosis, HBeAg,
and HBV DNA.
We further assessed whether the association between the ABO
blood group and HCC risk differed according to strata of other
known risk factors for HCC, including sex, HBeAg, HBV DNA
level, and cirrhosis. An interaction between ABO blood type and
sex or HBeAg was observed. The AOR (95% CI) for the
interaction term of blood type A, B, or AB and sex was 1.57 (0.78–
3.17), 3.33 (1.60–6.92), and 8.93 (1.91–41.64), respectively. The
AOR (95%) for the interaction term of blood type A, B, or AB and
HBeAg was 4.82 (2.58–9.02), 2.30 (1.23–4.32), and 2.64 (1.11–
6.30), respectively. As shown in Table 3, among male patients,
compared to subjects with blood type O, those with blood type A,
or B were at a greater HCC risk, whereas, among female patients,
compared with blood type O, those with blood type AB or B were
at a lesser HCC risk. A strong association between the ABO blood
Table 1. Demographic and clinical characteristics of hepatitis
B virus-related HCC cases and hospital cross-sectional CHB
controls: Univarite analyses.
Cases Controls
Variables
N=1105
(%)
N=5170
(%)
Univariate
OR (95%CI) P
Sex ,0.001
Female 169 (15.3) 1353 (26.2) 1
Male 936 (84.7) 3817 (73.8) 1.96 (1.65–2.34)
Age (years) ,0.001
30–39 82 (7.4) 2014 (39.0) 1
40–49 250 (22.6) 1385 (26.8) 4.43 (3.42–5.74)
50–59 470 (42.5) 1247 (24.1) 9.26 (7.25–11.83)
$60 303 (27.4) 524 (10.1) 14.20 (10.93–18.46)
City of residence 0.69
Jinan 464 (42.0) 2137 (41.3) 1
Other cities 641 (58.0) 3033 (58.7) 1.03 (0.90–1.17)
Family history
of liver cancer
0.76
No 1030 (93.2) 4832 (93.5) 1
Yes 75 (6.8) 338 (6.5) 1.04 (0.80–1.35)
Type 2 diabetes 0.013
No 1012 (91.6) 4842 (93.7) 1
Yes 93 (8.4) 328 (6.3) 1.36 (1.07–1.73)
HBeAg status ,0.001
HBeAg+ 256 (23.2) 3144 (60.8) 1
HBeAg2 849 (76.8) 2026 (39.2) 5.15 (4.43–5.98)
Cirrhosis ,0.001
No 346 (31.3) 3559 (68.8) 1
Yes 759 (68.7) 1611 (31.2) 4.85 (4.21–1.73)
HBVDNA.10
5
copies/mL
,0.001
No 559(50.6) 1153(22.3) 1
Yes 546(49.4) 4017(77.7) 0.28 (0.24–0.33)
HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; OR, odds ratio; CI,
confidence interval; HBeAg, hepatitis B e antigen.
doi:10.1371/journal.pone.0029928.t001
Table 2. ABO blood type and risk for hepatocellular carcinoma development in patients with chronic hepatitis B.
Cases Controls
ABO type N=1105 (%) N=5170 (%) Univariate OR (95%CI) AOR (95%CI) P
O 277 (25.1) 1462 (28.3) 1(reference) 1(reference)
A 321 (29.0) 1289 (24.9) 1.31 (1.06–1.61) 1.39 (1.05–1.83) 0.021
AB 132 (11.9) 609 (11.8) 1.13 (0.87–1.48) 0.85 (0.58–1.25) 0.409
B 375 (33.9) 1810 (35.0) 1.09 (0.89–1.32) 1.14 (0.87–1.49) 0.337
A+AB 453 (41.0) 1898 (36.7) 1.25 (1.04–1.52) 1.23 (0.95–1.59) 0.122
B+AB 507 (45.9) 2419 (46.8) 1.10 (0.91–1.32) 1.05 (0.81–1.35) 0.732
A+B+AB 828 (74.9) 3708 (71.7) 1.17 (0.99–1.39) 1.18 (0.93–1.49) 0.175
AOR, adjusted odds ratio; CI, confidence interval.
Logistic regression model adjusted for sex, age, type 2 diabetes, cirrhosis, HBeAg status, and HBVDNA.
doi:10.1371/journal.pone.0029928.t002
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patients, but not among HBeAg negative patients.
ABO blood group and severity of liver disease
As shown in Table 4, subjects with blood type A had more
severely impaired liver function. Compared with those with other
blood types, subjects with blood type A had a significantly high
prevalence of abnormal bilirubin and prolonged prothrombin
time. The distribution of cirrhosis was not significantly higher
among subjects with blood type A than among those with other
blood types. However, among the age,55 years group, the
prevalence of cirrhosis was significantly higher among subjects
with blood type A than among those with non-A. This indicated a
relationship between blood type A and early onset of cirrhosis.
Discussion
In this large case-control study in Chinese patients with CHB,
we observed a significantly elevated risk for HCC development
among those having blood type A, compared to those having
blood type O. Stratified analysis indicated that the association was
significant in men and not significant in women after adjusting
Table 3. ABO blood type and hepatocellular carcinoma risk in patients with chronic hepatitis B: stratified multivariate analyses.
ABO blood type
Factors O A AB B A+AB+B
Sex
Female
No. of cases/controls 64/395 47/311 7/130 51/517 105/958
AOR(95%CI) 1 (reference) 1.07(0.56–2.06) 0.11(0.02–0.53) 0.45(0.23–0.88) 0.55(0.32–0.93)
P value 0.83 0.005 0.019 0.027
Male
No. of cases/controls 213/1067 274/978 125/479 324/1293 723/2750
AOR(95%CI) 1(reference) 1.56(1.14–2.13) 1.15(0.76–1.73) 1.41(1.05–1.91) 1.42(1.09–1.86)
P value 0.005 0.511 0.024 0.009
HBeAg status
HBeAg positive
No. of cases/controls 47/927 100/708 19/377 90/1132 209/2217
AOR(95%CI) 1(reference) 4.92(2.83–8.57) 1.89(0.87–4.12) 2.25(1.28–3.96) 3.03(1.83–5.03)
P value ,0.001 0.11 0.005 ,0.001
HBeAg negative
No. of cases/controls 230/535 221/581 113/232 285/678 619/1491
AOR(95%CI) 1(reference) 0.81(0.58–1.12) 0.63(0.41–0.99) 0.90(0.66–1.23) 0.82(0.62–1.07)
P value 0.203 0.043 0.519 0.15
Cirrhosis
No
No. of cases/controls 100/995 105/866 41/432 100/1266 246/2564
AOR(95%CI) 1(reference) 1.10(0.67–1.79) 0.77(0.40–1.48) 0.85(0.52–1.41) 0.92(0.60–1.40)
P value 0.803 0.442 0.515 0.69
Yes
No. of cases/controls 177/467 216/423 91/177 275/544 582/1144
AOR(95%CI) 1(reference) 1.57(1.12–2.20) 0.86(0.54–1.38) 1.32(0.96–1.81) 1.32(1.0–1.75)
P value 0.008 0.537 0.090 0.05
HBV DNA.10
5copies/mL
No
No. of cases/controls 125/354 143/306 78/136 203/357 424/799
AOR(95%CI) 1(reference) 1.58(1.04–2.42) 1.08(0.63–1.84) 1.68(1.13–2.50) 1.52(1.07–2.17)
P value 0.033 0.776 0.011 0.02
Yes
No. of cases/controls 152/1108 168/983 54/473 172/1453 394/2909
AOR(95%CI) 1(reference) 1.22(0.85–1.77) 0.71(0.41–1.25) 0.80(0.56–1.16) 0.94(0.68–1.29)
P value 0.282 0.234 0.239 0.69
AOR, adjusted odds ratio; CI, confidence interval; HBeAg, hepatitis B e antigen. Logistic regression model adjusted for sex, age, type 2 diabetes, cirrhosis, HBeAg status,
and HBVDNA, and excluding the stratification variable.
doi:10.1371/journal.pone.0029928.t003
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those with blood type A or B had a significantly high HCC risk
that was independent of established HCC risk factors. To the best
of our knowledge, this is the first study showing an association
between the ABO blood group and HCC risk in patients with
CHB. However, a few previous studies showed relationships
between the ABO blood group and liver diseases, including HCC
[28,29,30,31], so the discovery of a relationship between the ABO
blood group and HCC is not surprising.
There are three reasons. First, the ABO blood group was
associated with the severity of liver disease, one of the major
predicators for HCC[5]. Poujol-Robert et al. reported that non-O
blood group is an independent risk factor for the progression of
liver fibrosis in HCV infection[28]. We also observed the
association between the ABO blood group and severity of liver
disease in our study population. Compared to those with blood
type O, those with blood type A had a significantly more severely
impaired liver function and an earlier onset of cirrhosis. These
indicated an association between the ABO blood group and liver
inflammation and fibrosis progression in patients with CHB.
The second reason that a relationship between the ABO blood
group and HCC is that the ABO blood group in conjunction with
several important cytokines known to be related to HCC
development, including EGF, TNF-a, sICAM-1, E-selectin, and
P-selectin et al [14,15,32,33,34].
The EGF receptor (EGFR) plays a link between inflammation
and liver cancer[35], and EGF gene polymorphisms have been
reported to be associated with HCC risk[10,12]. The binding of
epidermal growth EGF to EGFR is different in blood group A and
O, and loss or gain of expression of the A antigen may significantly
alter the binding properties of that protein affecting cell signaling
and growth[33]. An increase in the number of high affinity EGF
binding sites was observed in donors with blood group A1-
erythrocytes as compared to red cells taken from donors with
blood groups O and B. Glycosyltranferase specificity has broad
implications, beyond defining the ABO blood group. Glycocon-
jugates are important mediators of intercellular adhesion and
membrane signaling, two processes integral to malignant progres-
sion and spread [36]. The results of two recent GWAS which
reported the associations of SNPs at the ABO locus with plasma
levels of TNF-a and sICAM-1 also suggested a possible link
between the ABO blood group and HCC risk [14,15].
TNF is a pleiotropic cytokine involved not only in apoptosis,
but also with inflammation, hepatocyte protection, proliferation
and hepatocarcinogenesis [10,37]. Polymorphisms of TNF-a is
associated with HCC risk [11].The mechanism of the association
between the ABO blood group and TNF-a levels is not known.
Potentially, the TNF-a-ABO association is mechanistically
related to the association between E-selectin and ABO because
it is known that TNF-a induces E-selectin expression and is
positively associated with E-selectin levels[34,38,39]. Interesting-
ly, another GWAS reported the ABO is a major locus for serum
soluble E-selectin levels[34]. Whether the association between
levels of TNF-a and E-selectin can be explained by their
respective association with ABO is not clear.
ICAM-1 belongs to the immunoglobulin superfamily and plays
animportantroleinthe regulationofimmune response,particularly
in the antigen-presenting mechanism[40]. Plasma levels of sICAM-
1 have been reported to be associated with liver disease activity,
HCC occurrence and prognosis [17,20,21,22]. There is growing
evidence that the ABO blood group is highly significantly associated
withvariation in the levels of a number of biomarkers. A very recent
large-scale genomic study revealed sP-selectin levels were also
associated with ABO gene variants and the association was
accounted for by the A1 allele of the ABO blood group [32].
P-selectin, which has important roles in inflammatory processes,
tumor formation and metastasis, is a member of the selectin family
of adhesion molecules and is expressed mainly at the surface of
platelets and endothelial cells [41,42].These indicated a possible
association of ABO blood group with platelets. Platelets are key
actors in inflammation and critical for liver regeneration[43].
Interestingly, an association between the ABO blood group and
thrombocytopenia in patients with CHB was observed (unpub-
lished data). Thrombocytopenia has been regarded as a surrogate
of liver fibrosis and a predicator of HCC [44,45]. So, platelets
might mediate another possible inflammatory pathway connecting
the ABO blood group with liver fibrosis and HCC risk.
The physiological role of the ABO blood group still remains
enigmatic. The ABO blood type loci are not in linkage with genes
encoding ICAM, E-selectin, and P-selectin. ABO gene product
related glycosylation might influence sheding/cleavage of these
biomarkers from the endothelium, probably by glycosylation of P-
selectin, E-selectin, and ICAM-1[46]. Glycosylation could also
affect the clearance rate of sP-selectin, sE-selectin, and SICAM-1
from blood[32,34]. Decreased cleavage of adhesion molecules
from endothelial cells associated with A allele would mean more
adhesion molecules on the endothelial cells, increased adhesion
and inflammation[14]. In conclusion, collective data suggested
that the ABO blood type A might increase HCC risk by
connecting with several inflammatory pathways.
Table 4. ABO Blood type and severity of liver disease in chronic Hepatitis B.
O A AB B Non-A
Variables N (%) N (%) N (%) N (%) N (%) P
# P*
Bilirubin$50 mmol/L 314 (28.7) 322 (33.2) 113 (23.9) 327 (23.9) 754 (25.7) ,0.001 ,0.001
Albumin,35g/L 317 (28.9) 305 (31.4) 143 (30.2) 365 (26.7) 825 (28.1) 0.125 0.065
Prothrombin$18.5s 147 (13.4) 157 (16.2) 69 (14.6) 149 (10.9) 365 (12.4) 0.011 0.011
With Cirrhosis 644 (37.0) 639 (39.7) 268 (36.1) 819 (37.5) 1731 (37.1) 0.339 0.082
Age,55years 398 (30.8) 430 (35.2) 166 (29.9) 493 (29.9) 1057 (30.2) 0.032 0.004
Age$55years 246 (55.3) 209 (53.7) 102 (54.8) 326 (60.5) 674 (57.6) 0.314 0.304
#Chi-Square test among blood type O, A, AB, and B;
*A vs. Non-A.
doi:10.1371/journal.pone.0029928.t004
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might be another possible explanation for a relationship between
the ABO blood group and HCC. ABO blood antigens (A, B, H)
usually express on the surface of red blood cells and most epithelial
tissue, but not on hepatocytes, sinusoidal endothelial cells, and bile
canaliculi of the normal liver[47]. However, an increased ABH
expression or neoexpression was observed in HCC tissues. Terada
et al. reported that expression of the ABO blood group antigen
was more severe in atypical adenomatous hyperplasia and
hepatocellular carcinoma than in normal liver and chronic
hepatitis[30]. Okada found neoexpression of ABH blood group
antigens in HCC tissues[31]. Expression of H-active glycolipid was
enhanced in HCC tissues from the patients with blood types other
than O. These suggest that alterations in glycosyltransferase
specificity may occur during hepatocarcinogenesis. Recently,
Hoshida and colleagues provided new insights into genome-based
predictors of outcome in HCC patients [48].If abnormal
expression of the ABO blood group antigen in liver tissue could
predict HCC occurrence and outcome warrants further study.
We observed a gender difference in the association between the
ABO blood group and HCC risk, women with blood group AB or
B had a significantly lower HCC risk than those with blood group
O. Because of the small number of women with blood type AB in
the present study, the result should be considered with caution.
The underlying mechanism of the gender difference is unknown.
However, gender-related HCC risk difference is universal. The
overall male to female ratio of HCC is about 2:1 to 4:1[3]. A
gender difference was observed in that interleukin-6 signaling
promotes chemically induced HCC in genetic mouse models [49].
Several epidemiological studies also showed gender-based dimor-
phism for the association between other risk factors and HCC
development [50,51]. The present data indicated blood type A was
an additional HCC risk in the presence of other potent HCC
etiological risk factors. However, in women, a low HCC risk
population compared with men, the role of blood A antigen on
HCC development might be not potent enough to become a
significant additional HCC risk factor. Interestingly, another
finding that there was no significant association between blood
type A and HCC risk among subjects without cirrhosis, a low
HCC risk population compared with those with cirrhosis, also
supported the notion.
This study has several notable strengths. First its large sample
size enabled us to get a meaningful finding of the association
between the ABO blood group and HCC risk in patients with
CHB. Second, inpatient CHB controls in this study largely
represents the population from which the HBV-related HCC cases
arose. In areas of high HBV endemicity, persons with cirrhosis
have an approximately 3-fold higher risk for HCC than those with
chronic hepatitis but without cirrhosis and a 16-fold higher HCC
risk than the inactive carrier[5]. So, most HBV-related HCC arose
from CHB with or without cirrhosis, but not from an inactive
HBsAg carrier. Third, some possible confounding factors, such as
cirrhosis status, alcohol consumption, family history of liver
cancer, city of residence, HBeAg status, and HBV DNA were
evaluated in this study.
There are certain limitations to the study. First, the study
population was composed primarily of Chinese Han patients with
CHB, which somewhat limits the generalization of the results.
Further studies are necessary to confirm the association in other
population and in patients with other underlying liver diseases.
Second, not all HCC and cirrhosis cases were histologically
diagnosed. However, regarding HCC diagnosis, all patients with
nodules of 1–2 cm were confirmed with positive cytohistological
findings by ultrasound-guided liver biopsy. All of the patients were
re-evaluated during the hospitalization period. Moreover, hospi-
talized HCC patients in this study were followed-up every 1–3
months in the outpatient division of our hospital. Thus, it is
believed that there were no cases of misdiagnosed HCC, or, at the
very least, there were very few.
In conclusion, the results suggested that ABO blood type is
associated with the risk of HCC in Chinese patients with CHB.
The ABO blood group A increased HCC risk in patients with
CHB independent of other major HCC risk factors, and this
association was gender-related. Further studies are necessary to
confirm the association in patients with other underlying liver
diseases and to elaborate mechanisms by which ABO antigens
may influence HCC risk. In the future, it is possible that the ABO
blood type could be incorporated into predictive models for HBV-
related HCC, together with other human genetic, HBV-related
risk, and environmental factors.
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